Literature DB >> 15173097

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.

Gary J Kelloff1, Robert C Bast, Donald S Coffey, Anthony V D'Amico, Robert S Kerbel, John W Park, Raymond W Ruddon, Gordon J S Rustin, Richard L Schilsky, Caroline C Sigman, George F Vande Woude.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15173097     DOI： 10.1158/1078-0432.CCR-03-0783

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  13 in total

1.  Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Authors:  Robert J Kinders; Melinda Hollingshead; Scott Lawrence; Jiuping Ji; Brian Tabb; William M Bonner; Yves Pommier; Larry Rubinstein; Yvonne A Evrard; Ralph E Parchment; Joseph Tomaszewski; James H Doroshow
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

Review 2.  Biomarker method validation in anticancer drug development.

Authors:  J Cummings; T H Ward; A Greystoke; M Ranson; C Dive
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 3.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

4.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

Review 5.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 6.  The changing role of pathology in breast cancer diagnosis and treatment.

Authors:  Anthony S-Y Leong; Zhengping Zhuang
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

7.  Expression of prostate stem cell antigen is downregulated during flavonoid-induced cytotoxicity in prostate cancer cells.

Authors:  Qiang Zhang; Guangdong Cheng; Hongbin Qiu; Yuexin Wang; Jingtao Wang; Hui Xu; Tao Zhang; Lixin Liu; Ye Tao; Zhongjuan Ren
Journal:  Exp Ther Med       Date:  2017-06-21       Impact factor: 2.447

Review 8.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

10.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Authors:  John M L Ebos; Christina R Lee; James G Christensen; Anthony J Mutsaers; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.